Conditional logistic regression on the risk of mortality.

<p>Conditional logistic regression on the risk of mortality.</p

Use of psychotropic agents 1 year before and after the index date, with or without acute admission.

<p>Use of psychotropic agents 1 year before and after the index date, with or without acute admission.</p

Dementia cases and their propensity-score matched cohort.

<p>Dementia cases and their propensity-score matched cohort.</p

Additional file 2: Table S2. of Altered insula–default mode network connectivity in fibromyalgia: a resting-state magnetoencephalographic study

Functional connectivity between the right insula and default mode network (12 cortical areas) in healthy controls and patients with fibromyalgia. (DOCX 22 kb

Additional file 1: Table S1. of Altered insula–default mode network connectivity in fibromyalgia: a resting-state magnetoencephalographic study

Functional connectivity between the left insula and default mode network (12 cortical areas) in healthy controls and patients with fibromyalgia. (DOCX 20 kb

Crude mortality incidence rate ratio among the vascular dementia and non-vascular dementia groups.

<p>SD: standard deviation; IQR: interquartile range; py: person-year; IRR: incidence rate ratio; CI: confidence interval</p><p>Crude mortality incidence rate ratio among the vascular dementia and non-vascular dementia groups.</p

Baseline characteristics of the study samples.

<p>SD: standard deviation; AIDS: acquired immune deficiency syndrome</p><p>Baseline characteristics of the study samples.</p

Kaplan-Meier survival estimates.

<p>The median survival times were 9.23 years for the non-dementia group, 3.01 years for degenerative dementia without medications, 8.11 years for degenerative dementia with anti-dementia medications, 6.00 years for degenerative dementia with nootropics, and 9.03 years for degenerative dementia with both nootropic and anti-dementia medications.</p

Hazard ratios in the vascular dementia and degenerative dementia groups.

<p>Hazard ratios in the vascular dementia and degenerative dementia groups.</p

Development and validation of a dementia screening tool for primary care in Taiwan: Brain Health Test

<div><p>Objectives</p><p>To develop a simple dementia screening tool to assist primary care physicians in identifying patients with cognitive impairment among subjects with memory complaints or at a high risk for dementia.</p><p>Design</p><p>The Brain Health Test (BHT) was developed by several experienced neurologists, psychiatrists, and clinical psychologists in the Taiwan Dementia Society. Validation of the BHT was conducted in the memory clinics of various levels of hospitals in Taiwan.</p><p>Participants</p><p>All dementia patients at the memory clinics who met the inclusion criteria of age greater or equal to 50 years were enrolled. Besides the BHT, the Mini-Mental State Examination and Clinical Dementia Rating were used to evaluate the cognition state of the patients and the severity of dementia.</p><p>Results</p><p>The BHT includes two parts: a risk evaluation and a cognitive test (BHT-cog). Self or informants reports of memory decline or needing help from others to manage money or medications were significantly associated with cognitive impairment. Among the risk factors evaluated in the BHT, a total risk score greater or equal to 8 was defined as a high risk for dementia. The total score for the finalized BHT-cog was 16. When the cutoff value for the BHT-cog was set to 10 for differentiating dementia and a normal mental state, the sensitivity was 91.5%, the specificity was 87.3%, the positive predictive value was 94.8%, and the negative predictive value was 80.1% The area under the receiver operating characteristic curve between dementia and healthy subjects was 0.958 (95% CI = 0.941–0.975).</p><p>Conclusions</p><p>The BHT is a simple tool that may be useful in primary care settings to identify high-risk patients to target for cognitive screening.</p></div